Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Vor Biopharma ( (VOR) ).
On November 2, 2025, Vor Biopharma Inc. amended the employment agreement with its Chief Development Officer, Dr. Qing Zuraw, to include additional severance benefits in case of termination without cause or resignation after December 31, 2025. On November 3, 2025, Vor Bio announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer, bringing extensive experience in rheumatology and autoimmune disease research to the company, which aims to advance its clinical strategy and enhance patient outcomes.
The most recent analyst rating on (VOR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions globally.
Average Trading Volume: 356,574
Technical Sentiment Signal: Sell
Current Market Cap: $164.9M
Learn more about VOR stock on TipRanks’ Stock Analysis page.